Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

Zymeworks Inc. (NYSE:ZYME) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Zymeworks in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($0.51) per share for the quarter. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($1.17) EPS.

A number of other research analysts also recently issued reports on ZYME. Wells Fargo & Company boosted their price target on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price on the stock in a research note on Monday, December 16th. Citigroup raised their price target on Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. Lifesci Capital began coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price objective on the stock. Finally, HC Wainwright raised their target price on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Zymeworks Price Performance

Shares of Zymeworks stock opened at $12.93 on Thursday. Zymeworks has a one year low of $7.97 and a one year high of $17.70. The business’s 50 day simple moving average is $13.73 and its two-hundred day simple moving average is $13.67. The stock has a market capitalization of $899.63 million, a P/E ratio of -8.62 and a beta of 1.13.

Insider Transactions at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 58,306 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was acquired at an average cost of $12.64 per share, for a total transaction of $736,987.84. Following the purchase, the director now directly owns 17,030,604 shares of the company’s stock, valued at $215,266,834.56. This trade represents a 0.34 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Paul Andrew Moore sold 21,200 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $14.92, for a total transaction of $316,304.00. Following the completion of the transaction, the insider now directly owns 14,741 shares of the company’s stock, valued at approximately $219,935.72. This trade represents a 58.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 1,507,168 shares of company stock worth $19,339,774 and have sold 89,601 shares worth $1,336,847. Company insiders own 1.92% of the company’s stock.

Institutional Trading of Zymeworks

Large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its holdings in Zymeworks by 0.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 132,798 shares of the company’s stock worth $1,667,000 after buying an additional 650 shares in the last quarter. Nuveen Asset Management LLC increased its position in Zymeworks by 0.4% during the fourth quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock worth $3,031,000 after purchasing an additional 886 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Zymeworks by 6.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company’s stock valued at $214,000 after acquiring an additional 940 shares during the last quarter. Sterling Capital Management LLC lifted its stake in shares of Zymeworks by 781.5% in the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after purchasing an additional 1,524 shares during the last quarter. Finally, FMR LLC boosted its stake in Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after buying an additional 1,525 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.